促红细胞生成素治疗慢性心衰合并贫血的临床观察

目的:观察在慢性充血性心力衰竭合并贫血时标准治疗基础上加用促红细胞生成素(EPO)的临床疗效。方法:入选的57例伴有贫血的慢性充血性心力衰竭患者随机分为治疗组(30例)和对照组(27例)。对照组给予心衰的标准治疗,治疗组给予标准治疗同时给予EPO和铁剂,观察并比较两组治疗6个月前后Hb、心功能分级、LVEF及BNP。结果:治疗组Hb、心功能分级和LVEF较治疗前有显著改善(P<0.05);两组治疗后血浆BNP水平均下降,两组治疗后血浆BNP比较有差异(P<0.05)。结论:EPO治疗慢性充血性心力衰竭合并贫血患者有效,能改善心功能指标。

Erythropoietin in the treatment of chronic heart failure patients with anemia:Observation of clinical efficacy

Objective: To observe the clinical efficacy of erythropoietin(EPO) in the treatment of chronic heart failure(CHF) patients with anemia.Method:We randomly grouped 57 chronic heart failure patients with anemia as the treatment group(30cases) and control group(27 cases).Besides standard treatment,EPO and iron dextran were given in the treatment group,while the control group was only given standard treatment.The changes in Hb,NYHA,LVEF and BNP were monitored.Result:Hb,NYHA and LVEF were obviously improved in the treatment group(P<0.05),the levels of BNP were decreased in both groups after treatment(P<0.05),and the level of BNP in the treatment group was significantly lower than that of the control group(P<0.05).Conclusion:EPO is effective to CHF patients with anemia,and can improve the index of heart failure.